Security
Cadrenal Therapeutics, Inc. Common Stock · CVKD
CVKDNASDAQotherCurrentCIK 1937993Updated Oct 14, 2026
CVKD price & chart
Loading TradingView…
NASDAQ:CVKD on TradingView ↗About the company
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. The Company’s pipeline includes CAD-1005, tecarfarin, and frunexian. CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression. CAD-1005 has an Orphan Drug Designation (“ODD”) from the U.S. Food and Drug Administration (“FDA”) for prophylaxis of thrombosis in patients with HIT, FDA Fast Track designation for the treatment and prevention of HIT, and an orphan designation from the European Medicines Agency for the treatment of platelet-activating factor 4 disorders. Second-generation 12-LOX oral therapeutics (CAD-2000) are also in development for chronic indications.
In the news
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference ↗
Seeking Alpha
Cadrenal Therapeutics reports Q1 results ↗
Recent filings
Show 5 more recent filings
S-8 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
S-8 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 4,326,708Source | 10,123,533Source | 8,519,250Source | 778,174Source |
| Property, Plant and Equipment, NetUSD | 5,174Source | 6,944Source | 2,287Source | 1,013Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,007,789Source | 10,000,000Source | 8,402,500Source | — |
| Assets, CurrentUSD | 4,319,367Source | 10,112,797Source | 8,492,173Source | 727,596Source |
| Prepaid Expense and Other Assets, CurrentUSD | 200,140Source | 42,257Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | — | — | 20,998Source | 43,578Source |
| Other Assets, NoncurrentUSD | 2,167Source | 3,792Source | 3,792Source | 5,987Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,587,982Source | 2,683,958Source | 826,875Source | 6,329,324Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 2,338Source | 1,782Source | 13,022Source | 8,194Source |
| Additional Paid in CapitalUSD | 41,696,533Source | 33,160,576Source | — | 1,154,985Source |
| Retained Earnings (Accumulated Deficit)USD | -38,960,145Source | -25,722,783Source | -15,071,415Source | -6,714,329Source |
| Stockholders' Equity Attributable to ParentUSD | 2,738,726Source | 7,439,575Source | 7,692,375Source | -5,551,150Source |
| Additional Paid in Capital, Common StockUSD | — | — | 22,750,768Source | — |
| Liabilities and EquityUSD | 4,326,708Source | 10,123,533Source | 8,519,250Source | 778,174Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,587,982Source | 2,683,958Source | 826,875Source | 1,334,477Source |
| Operating Lease, Liability, CurrentUSD | — | — | 21,350Source | 22,288Source |
| Accounts Payable, CurrentUSD | 650,663Source | 1,502,468Source | 167,319Source | 404,897Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | 21,350Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 937,319Source | 1,181,490Source | 638,206Source | 863,564Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,939,896Source | 1,419,039Source | 710,381Source | 928,049Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -851,805Source | 1,335,149Source | -237,578Source | 404,897Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -12,601,666Source | -7,357,550Source | -3,530,323Source | -1,204,770Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -5,104Source | -6,537Source | -3,254Source | -2,279Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 5,104Source | 6,537Source | 3,254Source | 2,279Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,596,617Source | 8,979,529Source | 11,903,491Source | 1,239,635Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,007,789Source | 10,017,942Source | 8,402,500Source | 32,586Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,939,896Source | 1,419,039Source | 710,381Source | — |
| Amortization of Debt Issuance CostsUSD | — | — | 13,567Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | 66,913Source |
| DepreciationUSD | 6,874Source | 1,880Source | 1,980Source | 1,266Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -740,139Source | — |
| General and Administrative ExpenseUSD | 9,354,135Source | 6,753,726Source | 3,549,514Source | 2,307,503Source |
| Net Income (Loss) Attributable to ParentUSD | -13,237,362Source | -10,651,368Source | -8,357,086Source | -6,714,329Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -13,237,362Source | -10,651,368Source | — | — |
| Nonoperating Income (Expense)USD | 223,815Source | 309,251Source | -724,243Source | — |
| Operating ExpensesUSD | 13,461,177Source | 10,960,619Source | 7,632,843Source | 2,701,628Source |
| Operating Lease, ExpenseUSD | 26,875Source | 26,559Source | 26,555Source | 4,394Source |
| Proceeds from Issuance of Common StockUSD | 4,861,706Source | 5,143,594Source | — | 7,950Source |
| Proceeds from Stock Options ExercisedUSD | 48,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of RevenueUSD | — | — | 220,095Source | — |
| Operating Income (Loss)USD | -13,461,177Source | -10,960,619Source | -7,632,843Source | -2,701,628Source |
| Net Income (Loss) Attributable to ParentUSD | -13,237,362Source | -10,651,368Source | -8,357,086Source | -6,714,329Source |
| Earnings Per Share, BasicUSD per share | -6.64Source | -8.73Source | -0.62Source | -0.85Source |
| Earnings Per Share, DilutedUSD per share | -6.64Source | -8.73Source | -0.62Source | -0.85Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,993,757Source | 1,219,550Source | 13,491,980Source | 7,890,507Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,993,757Source | 1,219,550Source | 13,491,980Source | 7,890,507Source |
| Additional Financial Items | ||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 16.5Source | 16.5Source | — | — |
| General and Administrative ExpenseUSD | 9,354,135Source | 6,753,726Source | 3,549,514Source | 2,307,503Source |
| Income (Loss) Attributable to Parent, before TaxUSD | -13,237,362Source | 10,651,368Source | — | -6,714,329Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -13,237,362Source | 10,651,368Source | -8,357,086Source | -6,714,329Source |
| Interest ExpenseUSD | — | — | — | 40,192Source |
| Net Income (Loss) Attributable to Nonredeemable Noncontrolling InterestUSD | — | — | — | -6,714,329Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -13,237,362Source | -10,651,368Source | — | — |
| Nonoperating Income (Expense)USD | 223,815Source | 309,251Source | -724,243Source | — |
| Operating ExpensesUSD | 13,461,177Source | 10,960,619Source | 7,632,843Source | 2,701,628Source |
| Operating Lease, ExpenseUSD | 26,875Source | 26,559Source | 26,555Source | 4,394Source |
| Other ExpensesUSD | — | — | — | 4,012,701Source |
| Research and Development ExpenseUSD | 4,100,168Source | 4,205,013Source | 4,081,349Source | 136,802Source |
Offerings
Registration 333-297432
Registration 333-295200
Filing attachments
ea0307947ex99-1.htm · 8-K · 2026-10-07
Exhibit 99.1 CADRENAL THERAPEUTICS RETAINS TUNGSTEN ADVISORS TO LEAD FORMAL STRATEGIC PROCESS TO MAXIMIZE VALUE OF ITS ORPHAN THROMBO-INFLAMMATORY THERAPEUTICS Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005 Cadrenal has received strong interest from potential strategic partners Cadrenal will explore all strategic alternatives including corporate partnerships and other strategic transactions …
Read attachment ↗ea030399701ex99-1.htm · 8-K · 2026-08-31
EX-99.1 2 ea030399701ex99-1.htm PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON AUGUST 31, 2026 Exhibit 99.1 Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated $2 Bi…
Read attachment ↗ea030204201ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ea030204201ex99-1.htm PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON AUGUST 13, 2026 Exhibit 99.1 Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding PONTE VEDRA, F…
Read attachment ↗ea029866901ex99-1.htm · 8-K · 2026-07-21
EX-99.1 2 ea029866901ex99-1.htm PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON JULY 21, 2026 Exhibit 99.1 FOR IMMEDIATE RELEASE Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation: Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions Company is exploring developmen…
Read attachment ↗ea029666601ex4-1.htm · 8-K · 2026-07-01
EX-4.1 2 ea029666601ex4-1.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES A…
Read attachment ↗ea029666601ex4-2.htm · 8-K · 2026-07-01
EX-4.2 3 ea029666601ex4-2.htm FORM OF SERIES C-1 WARRANT Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES A…
Read attachment ↗